Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael I. Halstead
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Employees
- 100
- Beta
- 0.56
- Country
- CA
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 33.99
Financials
Revenue
$0.00-100.0%Net Income
$-46.60MEBITDA
$-47.81MFree Cash Flow
$-36.44MEPS (diluted)
$-0.89Shares Outstanding (diluted)
52.32M+14411.6%Operating Expenses
$47.81MCash & Debt
$166.17MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $-44.68M | $-147.05M | $-4.23 |
| 2025 | $472.3K | $-113.14M | $-5.59 |
| 2024 | $0.00 | $-78.08M | $-3.91 |
| 2023 | $251.0K | $-47.49M | $-9.73 |
| 2022 | $167.8K | $-67.63M | $-15.36 |
| 2021 | $864.0K | $-32.22M | $-12.24 |
| 2020 | $0.00 | $-1.94M | $-1.48 |
| 2019 | $0.00 | $-101.0K | $-0.28 |
| 2018 | $0.00 | $-220.8K | $-0.69 |
| 2017 | $0.00 | $-127.0K | $-0.35 |
Valuation
HELPhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·5d ago·Neutral
Helus Pharma Announces Completion of Legal Name Change NEW YORK and TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the Company's legal name has been changed from “Cybin Inc.” to “Helus Pharma Inc.” effective October 1, 2026. The name change was approved by shareholders at the Company'…
View source ↗ - Newsglobenewswire.com·13d ago·Neutral
…nces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the voting results for each of the matters presented at the Company's annual and special meeting of shareholders held on September 22, 20…
View source ↗ - Newsglobenewswire.com·49d ago·Negative
Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board Former Intra-Cellular Therapies, Inc. (“Intra-Cellular”) executives bring complementary experience in organizational scale-up, central nervous system (“CNS”) drug development, regulatory approvals and commercialization
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights - Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization -
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.67 per share
Typical surprise -14.7% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.91 vs $-0.84miss
- Tue, Jun 30$-0.96 vs $-1.04beat
- Fri, Feb 13$-0.99 vs $-0.53miss
- Thu, Nov 13$-1.39 vs $-0.74miss
- Wed, Aug 13$-1.10 vs $-0.96miss
- Tue, Jul 1$-1.01 vs $-0.85miss
Estimates and results for HELP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HELP officers and directors.
- Bought
- $39k
- Sold
- —
1 trade
0 trades
- Cavers Gregbought
4 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in HELP.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.